Skip to Main Content

Author Details

Patrick Micke
Uppsala University
1997
160
45
Emma Lundberg (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37382890Tumor Heterogeneity Confounds Lymphocyte Metrics in Diagnostic Lung Cancer Biopsies.Arch Pathol Lab Med2024
37801008Distinct microRNA Signature and Suppression of ZFP36L1 Define ASCL1-Positive Lung Adenocarcinoma.Mol Cancer Res2024
36083003Fibroblast subsets in non-small cell lung cancer: Associations with survival, mutations, and immune features.J Natl Cancer Inst2023
37349623Diagnostic gastrointestinal markers in primary lung cancer and pulmonary metastases.Virchows Arch2023
37341056Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer.Mol Oncol2023
37139184Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer.Oncoimmunology2023
36963351Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer.Eur J Cancer2023
36724681An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers.EBioMedicine2023
35236568Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.Eur J Cancer2022
35574381Prognostic Significance of the Loss of Heterozygosity of <i>KRAS</i> in Early-Stage Lung Adenocarcinoma.Front Oncol2022
35429913Highly elevated systemic inflammation is a strong independent predictor of early mortality in advanced non-small cell lung cancer.Cancer Treat Res Commun2022
36613642Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA Signature.Int J Mol Sci2022
36636421Comparison of ROS1-rearrangement detection methods in a cohort of surgically resected non-small cell lung carcinomas.Transl Lung Cancer Res2022
35990519Expression of cartilage oligomeric matrix protein in periampullary adenocarcinoma is associated with pancreatobiliary-type morphology, higher levels of fibrosis and immune cell exclusion.Oncoimmunology2022
33547095Difficulties in diagnostics of lung tumours in biopsies: an interpathologist concordance study evaluating the international diagnostic guidelines.J Clin Pathol2022
35158957Spatial Immunology in Liver Metastases from Colorectal Carcinoma according to the Histologic Growth Pattern.Cancers (Basel)2022
33293426Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.Cancer Res2021
33576873PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.Cancer Immunol Immunother2021
33706249The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types.EBioMedicine2021
33706022Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation.Lung Cancer2021
34960725Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection.Viruses2021
34789779TGF-β-mediated epithelial-mesenchymal transition and tumor-promoting effects in CMT64 cells are reflected in the transcriptomic signature of human lung adenocarcinoma.Sci Rep2021
34772928An integrative proteomics method identifies a regulator of translation during stem cell maintenance and differentiation.Nat Commun2021
34771707The Immune Landscape of Colorectal Cancer.Cancers (Basel)2021
34128105Targeting hepatocyte growth factor in epithelial-stromal interactions in an in vitro experimental model of human periodontitis.Odontology2021
33984662FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response.Eur J Cancer2021
34206510Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade.Cancers (Basel)2021
34202448High Density of NRF2 Expression in Malignant Cells Is Associated with Increased Risk of CNS Metastasis in Early-Stage NSCLC.Cancers (Basel)2021
34339045Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer.J Pathol2021
33257846Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene.Cell Death Differ2021
33310622Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.Lung Cancer2021
33214079Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.Clin Lung Cancer2021
32534174ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma.Cancer Lett2020
31672904Platelet-derived growth factor receptor β activation and regulation in murine myelofibrosis.Haematologica2020
32028050WITHDRAWN: Characterization of Patterns of Immune Cell Infiltration in NSCLC.J Thorac Oncol2020
31913660Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers.Arch Pathol Lab Med2020
33315908PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3.PLoS One2020
32715618The protein expression profile of ACE2 in human tissues.Mol Syst Biol2020
33014851The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model.Front Oncol2020
33013928Topographical Distribution and Spatial Interactions of Innate and Semi-Innate Immune Cells in Pancreatic and Other Periampullary Adenocarcinoma.Front Immunol2020
32325417An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer.Eur J Cancer2020
32491279Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non-small cell lung cancer.Cancer Med2020
32129882Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma.Int J Cancer2020
30639618Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC.J Thorac Oncol2019
31357969Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung.BMC Cancer2019
31319978Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.Lung Cancer2019
31200831c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.Lung Cancer2019
31018250NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy.Int J Cancer2019
30926355Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray.Clin Lung Cancer2019
30914778A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer.Sci Rep2019
  • 1 - 50 of 160

Recommended Authors

Institut fur Pathologie, Universitatsklinikum Heidelberg
Career Start Year 2016
Number of shared co-authors 0
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Career Start Year 2015
Number of shared co-authors 0
Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Universite Laval
Career Start Year 2013
Number of shared co-authors 1
UPMC Hillman Cancer Center
Career Start Year 2012
Number of shared co-authors 0
University of Navarra
Career Start Year 2010
Number of shared co-authors 1
National Cancer Center Exploratory Oncology Research & Clinical Trial Center
Career Start Year 2008
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute
Career Start Year 2008
Number of shared co-authors 0
Quantitative Biomedical Research Center
Career Start Year 2007
Number of shared co-authors 0
University of Pisa
Career Start Year 2006
Number of shared co-authors 0
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 1
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 2
Olivia Newton-John Cancer Research Institute
Career Start Year 2003
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Career Start Year 2002
Number of shared co-authors 2
Fondazione IRCCS Istituto Nazionale dei Tumori
Career Start Year 2000
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1997
Number of shared co-authors 0
St Vincent's Hospital
Career Start Year 1997
Number of shared co-authors 0
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1996
Number of shared co-authors 0
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Career Start Year 1996
Number of shared co-authors 25
Norris Comprehensive Cancer Center, University of Southern California
Career Start Year 1995
Number of shared co-authors 0
German Cancer Research Center (DKFZ)
Career Start Year 1993
Number of shared co-authors 2
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Career Start Year 1993
Number of shared co-authors 0
Institute of Pathology, Heidelberg University Hospital
Career Start Year 1991
Number of shared co-authors 0
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 8
Center for Cancer Research, National Cancer Institute
Career Start Year 1988
Number of shared co-authors 3
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Career Start Year 1986
Number of shared co-authors 0
University of California, USA Cardiovascular Research Institute san francisco
Career Start Year 1981
Number of shared co-authors 0
Yale University School of Medicine
Career Start Year 1980
Number of shared co-authors 4
University Health Network, University of Toronto
Career Start Year 1972
Number of shared co-authors 1

Collaborators

Uppsala University
Co-authored papers 42
Lund University
Co-authored papers 34
Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund
Co-authored papers 33
Lund University
Co-authored papers 31
Uppsala University
Co-authored papers 26
Yale University School of Medicine
Co-authored papers 15
Uppsala University
Co-authored papers 14
TU Dortmund University
Co-authored papers 13
Ohu University School of Pharmaceutical Sciences
Co-authored papers 11
Uppsala University
Co-authored papers 10
Co-authored papers 10
Uppsala University
Co-authored papers 9
Umea University
Co-authored papers 8
Nihon University School of Dentistry
Co-authored papers 8
KTH Royal Institute of Technology
Co-authored papers 6
Stockholm University
Co-authored papers 5
The Icelandic Cancer Registry
Co-authored papers 5
Uppsala University
Co-authored papers 5
KTH Royal Institute of Technology
Co-authored papers 3
KTH Royal Institute of Technology
Co-authored papers 3
RIKEN Center for Integrative Medical Sciences
Co-authored papers 2
RIKEN Center for Integrative Medical Sciences
Co-authored papers 2
Uppsala University
Co-authored papers 2
Co-authored papers 2
Telethon Kids Institute, University of Western Australia
Co-authored papers 2
KTH-Royal Institute of Technology
Co-authored papers 2
RIKEN Center for Integrative Medical Sciences
Co-authored papers 2
Cerevance Ltd
Co-authored papers 2
University of Gothenburg
Co-authored papers 2
RIKEN Center for Integrative Medical Sciences
Co-authored papers 2